Pat nt Claims

1. A transdermal system comprising:
a) a cover layer (1, 11),
b) a water-soluble material that can be dissolved by moisture on the skin,
c) an optionally active-ingredient-containing adhesive layer (4, 14),
and
d) a protective layer that is detachable therefrom,
the transdermal system being characterised by an active-ingredient-containing polymer layer (3) in which the active ingredient is present in the form of a non-water-miscible active ingredient solution or a non-water-miscible active ingredient dispersion in a water-soluble polymer.

2. A transdermal system according to claim 1, ***characterised*** by an adhesive layer (2) arranged between the active-ingredient-containing polymer layer (3) and the cover layer (1), which adhesive layer (2) optionally contains active ingredient.

3. A transdermal system according to ~~one of the preceding claims,~~ ***characterised*** in that the active ingredient(s) in the polymer layer (3) is(are) not miscible with water.

4. A transdermal system according to ~~any one of the preceding claims;~~ ***characterised*** in that the hydrophilic polymer comprises gelatin or cellulose esters or ethers or derivatives thereof.

5. A transdermal system according to ~~any one of the preceding claims~~, ***characterised*** in that the polymer layer (3) is perforated, so that at least the adhesive layer (4) can come into contact with layers (1, 2) disposed on the other side of the polymer layer (3).

6. A transdermal system according to ~~any one of the preceding claims, characterised~~ in that the active ingredients are present in the relevant layers in the form of (an) immobilised active ingredient solution(s) or dispersion(s).

7. A transdermal system according to ~~any one of claims 2 to 6,~~ ***characteris d*** in that
a) the layers (2) and (4) are free of active ingredient, or

b) the layer (2) contains active ingredient and the layer (4) is free of active ingredient, or
c) the layer (2) is free of active ingredient and the layer (4) contains active ingredient, or
d) the layers (2) and (4) contain active ingredient.

8. A transdermal system according to ~~any one of the preceding claims~~, ***characterised*** in that the thickness of the layer (4) is from 10 to 300 µm, preferably from 30 to 100 µm.

9. A transdermal system according to ~~any one of claims 2 to 8~~, ***characterised*** in that the thickness of the layer (2) is from 1 to 300 µm, preferably from 3 to 100 µm.

10. A process for the manufacture of a transdermal system according to ~~any one of the preceding claims~~, ***characterised*** in that, in a freely selectable order, an adhesive layer (4) is applied to a protective layer (5), an active-ingredient-containing polymer layer (3) optionally having perforations is applied to the adhesive layer (4), a further adhesive layer (2) is optionally applied to the polymer layer (3), and a cover layer (1) is applied to the top layer.

11. A transdermal system according to ~~any one of the preceding claims, characterised~~ in that the cover layer (1, 11) comprises one or more water-vapour-impermeable material(s), especially polyester, preferably polyterephthalic acid ester, or polypropylene or polyethylene, or one or more water-vapour-impermeable material(s), especially polyurethane, or one or more woven or non-woven fabrics.

12. A transdermal system according to ~~any one of the preceding claims~~, ***characterised*** in that the adhesive layer (4, 14) and/or the adhesive layer (2) are, independently of each other, pressure-sensitive adhesive layers.

13. A transdermal system according to ~~any one of the preceding claims~~, ***characterised*** in that the adhesive layer (4, 14) and/or the adhesive layer (2) contain a net, a non-woven fabric or a woven fabric, the thread or fibre thickness thereof preferably being less than the thickness of the adhesive layer.

14. A transdermal system according to ~~any one of the preceding claims~~, ***charact ris d*** in that the protective layer (5, 15) is re-detachable and is especially a siliconised plastics

film or a silicone paper.

15. A transdermal system according to ~~any one of the preceding claims, characterised~~ in that the active ingredient comprises testosterone, nitroglycerine or mixtures thereof.

16. The use of a transdermal system according to ~~any one of the preceding claims~~ for the treatment of Angina pectoris, for nicotine withdrawal or in the case of testosterone deficiency symptoms.